A Randomized Controlled Trial to evaluate the Efficacy and Safety of Alternate day therapy with Atorvastatin and Fenofibrate combination in the treatment of Mixed Dyslipidemia.

IL Investigator Initiated Trial0 个研究点目标入组 110 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1) Adult Male and Female patients of age >18years and <= 65years who are diagnosed as Mixed Dyslipidemia and meet the criteria for pharmacological treatment as per updated NCEP-ATP III guidelines 2) Fasting LDL levels >= 130mg/dL, Fasting TGL levels >= 200mg/dL, Fasting Total Cholesterol levels >= 200mg/dL 3) Patients who failed to achieve lipid target goals as per updated NCEP-ATP III guidelines with Therapeutic life style changes or with other modalities of treatment 4) Eligible patients who are willing to participate in the study by voluntarily signing the Informed Consent Form

•1) Patients who are already on treatment with statins or fibrates. 2) Patients allergic/hypersensitive to either Atorvastatin or Fenofibrate. 3) Pregnant and Lactating women. 4) Women of child bearing age not using acceptable methods of contraception. 5) Patients with active liver disease having elevated liver enzymes. 6) Patients with Uncontrolled Diabetes Mellitus with FBS >200mg/dL even after therapy with OHA/Insulin. 7) Patients with elevated Creatine Kinase levels /muscular disorders. 8) Post-MI, Post-CABG, Post-PTCA, Post-Stroke patients within six months of occurrence of the event. 9) CCF patients receiving Digoxin. 10) Patients unwilling to give informed consent. 11) Mentally challenged patients who are unable to give informed consent

发起方

IL Investigator Initiated Trial